Considerations for use of Ebola vaccine during an emergency response.
Ebola infection
Ebola virus vaccines
Emergencies
Outbreaks
Strategic planning
Vaccination
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
15 11 2019
15 11 2019
Historique:
received:
31
05
2017
revised:
21
07
2017
accepted:
24
08
2017
pubmed:
12
9
2017
medline:
30
7
2020
entrez:
12
9
2017
Statut:
ppublish
Résumé
Vaccination against Ebola virus disease is a tool that may limit disease transmission and deaths in future outbreaks, integrated within traditional Ebola outbreak prevention and control measures. Although a licensed Ebolavirus vaccine (EV) is not yet available, the 2014-2016 West African Ebola outbreak has accelerated EV clinical trials and given public health authorities in Guinea, Liberia, and Sierra Leone experience with implementation of emergency ring vaccination. As evidence supporting the use of EV during an outbreak response has become available, public health authorities in at-risk countries are considering how to integrate EV into future emergency Ebola responses and for prevention in high-risk groups, such as healthcare workers and frontline workers (HCW/FLWs), even before an EV is licensed. This review provides an overview of Ebola epidemiology, immunology, and evidence to inform regional and country-level decisions regarding EV delivery during an emergency response and to at-risk populations before a licensed vaccine is available and beyond. Countries or regions planning to use EV will need to assess factors such as the likelihood of a future Ebolavirus outbreak, the most likely species to cause an outbreak, the availability of a safe and effective EV (unlicensed or licensed) for the affected population, capacity to implement Ebola vaccination in conjunction with standard Ebola outbreak control measures, and availability of minimum essential resources and regulatory requirements to implement emergency Ebola vaccination. Potential emergency vaccination strategies for consideration include ring or geographically targeted community vaccination, HCW/FLW vaccination, and mass vaccination. The development of guidelines and protocols for Ebola vaccination will help ensure that activities are standardized, evidence-based, and well-coordinated with overall Ebola outbreak response efforts in the future.
Identifiants
pubmed: 28890191
pii: S0264-410X(17)31156-8
doi: 10.1016/j.vaccine.2017.08.058
pmc: PMC5842136
mid: NIHMS937627
pii:
doi:
Substances chimiques
Ebola Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7190-7200Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Investigateurs
Sarah D Bennett
(SD)
Rosalind J Carter
(RJ)
John T Redd
(JT)
Barbara J Marston
(BJ)
Informations de copyright
Published by Elsevier Ltd.
Références
Emerg Infect Dis. 2016 Jul;22(7):
pubmed: 27191253
Curr Opin Virol. 2016 Apr;17:138-144
pubmed: 27180074
Emerg Infect Dis. 2010 Jul;16(7):1087-92
pubmed: 20587179
Clin Vaccine Immunol. 2010 Apr;17(4):572-81
pubmed: 20181765
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9
pubmed: 22411795
Nature. 2015 Nov 26;527(7579):453-5
pubmed: 26607539
J Infect Dis. 1999 Feb;179 Suppl 1:S87-91
pubmed: 9988169
N Engl J Med. 2015 Dec 17;373(25):2448-54
pubmed: 26465384
PLoS Negl Trop Dis. 2016 Aug 18;10(8):e0004802
pubmed: 27537602
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
Wkly Epidemiol Rec. 2015 Dec 11;90(50):681-99
pubmed: 26685390
J Infect Dis. 2016 Nov 15;214(10):1475-1476
pubmed: 27142204
Clin Infect Dis. 2016 Nov 15;63(10):1353-1356
pubmed: 27585800
J Infect Dis. 1999 Feb;179 Suppl 1:S24-7
pubmed: 9988161
Bull World Health Organ. 1978;56(2):271-93
pubmed: 307456
J Infect Dis. 1999 Feb;179 Suppl 1:S1-7
pubmed: 9988155
Ther Adv Vaccines. 2015 Sep;3(5-6):125-38
pubmed: 26668751
Clin Infect Dis. 2015 Oct 1;61(7):1135-40
pubmed: 26129757
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
MMWR Morb Mortal Wkly Rep. 2014 Oct 17;63(41):925-9
pubmed: 25321070
MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1168-71
pubmed: 25503921
Lancet. 2015 Aug 1;386(9992):432
pubmed: 26251391
J Infect Dis. 1999 Feb;179 Suppl 1:S98-101
pubmed: 9988171
Ann Intern Med. 2015 Jan 6;162(1):11-7
pubmed: 25347321
PLoS Pathog. 2010 May 20;6(5):e1000904
pubmed: 20502688
JAMA. 2017 Mar 14;317(10):1075-1077
pubmed: 28291882
PLoS Negl Trop Dis. 2011 Jun;5(6):e1175
pubmed: 21666792
Cell. 2016 Jan 28;164(3):392-405
pubmed: 26806128
J Infect Dis. 1999 Feb;179 Suppl 1:S28-35
pubmed: 9988162
N Engl J Med. 2016 Aug 11;375(6):587-96
pubmed: 27509108
Lancet. 1995 May 20;345(8960):1271-4
pubmed: 7746057
Lancet Infect Dis. 2015 Mar;15(3):320-6
pubmed: 25619149
J Virol. 2009 Jul;83(14):7296-304
pubmed: 19386702
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
Emerg Infect Dis. 2016 Jan;22(1):105-8
pubmed: 26691346
Vaccine. 2017 Dec 14;35(49 Pt B):6915-6923
pubmed: 28716555
Expert Rev Vaccines. 2016 Sep;15(9):1101-12
pubmed: 27160784
Sci Data. 2015 May 26;2:150019
pubmed: 26029377
Euro Surveill. 2015 Jan 22;20(3):null
pubmed: 25635320
MMWR Morb Mortal Wkly Rep. 2001 Feb 9;50(5):73-7
pubmed: 11686289
Vaccine. 2016 Apr 4;34(15):1767-72
pubmed: 26928073
N Engl J Med. 2017 Oct 12;377(15):1428-1437
pubmed: 26465681
Bull World Health Organ. 1978;56(2):247-70
pubmed: 307455
Expert Rev Vaccines. 2016 Nov;15(11):1421-1430
pubmed: 27078187
N Engl J Med. 2015 Jun 18;372(25):2423-7
pubmed: 25950269
J Infect Dis. 1999 Feb;179 Suppl 1:S76-86
pubmed: 9988168
Am J Trop Med Hyg. 2016 Sep 7;95(3):654-62
pubmed: 27382077
Expert Rev Vaccines. 2014 Apr;13(4):521-31
pubmed: 24575870
MMWR Morb Mortal Wkly Rep. 2014 Nov 21;63(46):1077-81
pubmed: 25412067
MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):386-8
pubmed: 25879897
J Autoimmun. 2014 Dec;55:1-9
pubmed: 25260583
J Infect Dis. 1999 Feb;179 Suppl 1:S263-7
pubmed: 9988193
J Infect Dis. 1999 Feb;179 Suppl 1:S92-7
pubmed: 9988170
BMC Infect Dis. 2011 Dec 28;11:357
pubmed: 22204600
J Infect Dis. 1999 Feb;179 Suppl 1:S170-6
pubmed: 9988181
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Expert Rev Vaccines. 2015;14(11):1471-8
pubmed: 26325242
Lancet Infect Dis. 2015 May;15(5):507-8
pubmed: 25932579
Emerg Infect Dis. 2016 Apr;22(4):759-60
pubmed: 26982461
JAMA Neurol. 2017 Sep 1;74(9):1141-1143
pubmed: 28715541
N Engl J Med. 2014 Nov 27;371(22):2083-91
pubmed: 25317743
PLoS Negl Trop Dis. 2016 Nov 2;10(11):e0005093
pubmed: 27806049
PLoS Negl Trop Dis. 2015 Jun 15;9(6):e0003838
pubmed: 26076007
PLoS Negl Trop Dis. 2015 May 29;9(5):e0003794
pubmed: 26024528
J Virol. 2004 Apr;78(8):4330-41
pubmed: 15047846
PLoS Med. 2016 Nov 15;13(11):e1002170
pubmed: 27846234
Expert Rev Vaccines. 2016 Sep;15(9):1093-100
pubmed: 27010528
J Infect Dis. 2007 Nov 15;196 Suppl 2:S142-7
pubmed: 17940942
Sci Rep. 2015 Oct 30;5:15818
pubmed: 26515898
Emerg Infect Dis. 2010 Dec;16(12):1969-72
pubmed: 21122234
Clin Infect Dis. 2015 Mar 15;60(6):974-5
pubmed: 25501984
J Infect Dis. 2011 Nov;204 Suppl 3:S761-7
pubmed: 21987748
Nature. 2016 May 5;533(7601):100-4
pubmed: 27147028
Mucosal Immunol. 2008 Sep;1(5):372-81
pubmed: 19079201
PLoS One. 2015 Mar 20;10(3):e0118881
pubmed: 25793502
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):479-81
pubmed: 25950255
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2337-2342
pubmed: 28193880
Lancet. 2016 May 7;387(10031):1887-9
pubmed: 27203633